Yahoo! Canada Finance: Biotechnology Industry News

Bentley Pharmaceuticals & Teva Pharmaceutical Industries Ltd. Merger Consideration Established at $14.82 Per Share

Thu, 03 Jul 2008 21:31:02 GMT

Business Wire - Bentley Pharmaceuticals, Inc. (“Bentley”) (NYSE: BNT) announced that the aggregate cash purchase price for its acquisition by Teva Pharmaceutical Industries Ltd. (“Teva”) has been adjusted in accordance with the merger agreement after completion of the previously announced taxable spin-off of its drug delivery business, CPEX Pharmaceuticals, Inc. (“CPEX”)(NASDAQ: CPEX).

Introgen Reduces Development Staff to Focus on Commercial Activities after ADVEXIN Regulatory Filings in U.S. and Europe

Thu, 03 Jul 2008 21:30:17 GMT

Business Wire - Introgen Therapeutics, Inc. (NASDAQ:INGN) today announced a re-allocation of employees to focus on regulatory review and commercial activities.

Immunotec announces new Chief Operating Officer

Thu, 03 Jul 2008 20:14:38 GMT

CNW Group - Immunotec Inc. (TSX-V :IMM) today announced the appointment of Daniel L. Murphy as Executive Vice President...

Savient Announces U.S. Court of Appeals Affirmation of the Dismissal of Securities Class Action Complaint

Thu, 03 Jul 2008 19:43:25 GMT

Business Wire - Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) today announced that the United States Court of Appeals for the Third Circuit has entered a Judgment affirming the decision of the U.S.

BIO Applauds U.S. Adoption for GE Corn, Cotton, Soybeans

Thu, 03 Jul 2008 19:09:17 GMT

Business Wire - American farmers have adopted genetically engineered (GE) crops widely since their introduction in 1996, especially corn, cotton and soybean varieties, according to a new USDA report.

Fluxion Biosciences Wins R&D 100 Award

Thu, 03 Jul 2008 18:21:22 GMT

Business Wire - Fluxion Biosciences, a leading provider of functional cell biology systems for life science research and drug discovery, today announced that it has won a 2008 R&D 100 Award for its BioFlux™ 200 System.

Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntington's Disease

Thu, 03 Jul 2008 18:14:34 GMT

PRNewswire - Medivation, Inc. (Nasdaq: MDVN) today announced that it will hold a teleconference at 5:00 p.m. EDT...

Bio-Bridge Science Announces $2.775 Million Private Placement

Thu, 03 Jul 2008 17:58:24 GMT

Business Wire - Bio-Bridge Science, Inc. (OTCBB:BGES), a biotechnology company engaged in the commercial development of vaccines for the prevention and treatment of human infectious diseases announced today that it had closed a private placement of its investment units.

Bioheart, Inc., Board Appoints Howard J. Leonhardt Chief Executive Officer

Thu, 03 Jul 2008 17:05:18 GMT

PRNewswire - Bioheart, Inc., (Nasdaq: BHRT) a biotechnology company that is focused on the development of autologous (patient-derived) cell therapies and devices for the treatment of chronic and acute heart damage, today announced that its Board of Directors appointed Howard J. Leonhardt, Bioheart's co-founder, Chairman of the Board and Chief Technology Officer, to serve as Chief Executive Officer effective as of July 1, 2008.

Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients

Thu, 03 Jul 2008 16:57:26 GMT

Business Wire - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received marketing approval for RELISTOR™ (methylnaltrexone bromide) subcutaneous injection from the European Commission.

Medicago Receives Contribution From NRC-IRAP for Seasonal Flu Vaccine Program

Thu, 03 Jul 2008 16:49:14 GMT

Marketwire - Medicago Inc. (TSX VENTURE:MDG) today announced it has been awarded a non-refundable contribution of up to $279,700 from Canada's National Research Council Industrial Research Assistance Program ("NRC-IRAP") to support the development of the Company's seasonal influenza Virus-Like Particles (VLP) vaccine program.

Cell Biosciences Strengthens Management Team

Thu, 03 Jul 2008 16:48:46 GMT

PRNewswire - Cell Biosciences, Inc., a provider of ultrasensitive protein detection and characterization systems to life science researchers, today announced three key management team additions.

Today's Caregiver Magazine Celebrates 70th Fearless Caregiver Conference with Free Tickets to Boynton Event

Thu, 03 Jul 2008 14:03:06 GMT

Business Wire - Today's Caregiver magazine announced today that it will make available a limited number of tickets for family caregivers to attend the Palm Beach Fearless Caregiver Conference on July 16th at Benvenuto's in Boynton Beach.

The Institut de la Vision and Iris Pharma Join Forces to Strengthen the Bond between the Private and Public Sectors, and between Industry and Academic

Thu, 03 Jul 2008 14:02:05 GMT

Business Wire - The Institut de la Vision, a research center exclusively dedicated to eye diseases, has been the industry's benchmark on vision-related issues since its opening in March 2008.

PerkinElmer Second Quarter Earnings and Conference Call Notification

Thu, 03 Jul 2008 14:01:42 GMT

Business Wire - PerkinElmer, Inc. (NYSE: PKI) today announced that on Thursday, July 24, 2008, after market close, the Company will release second quarter 2008 results.

Advanced Life Sciences Added to Russell Microcap Index

Thu, 03 Jul 2008 13:31:14 GMT

PRNewswire - Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases, today announced that it was added to the Russell Microcap(R) Index after the Russell Investment Group reconstituted its comprehensive set of U.S. and global equity indexes on June 27, 2008.

BioCurex Comments On Market Activity

Thu, 03 Jul 2008 13:30:21 GMT

PrimeNewswire - BioCurex Inc. (OTCBB:BOCX) is aware of the recent trading activity in the company's stock and notes that there has been no material change in the business of the Company to support this activity.

PerkinElmer Establishes ViaCord Research Institute(TM) to Further Cord Blood Stem Cell Advancements

Thu, 03 Jul 2008 13:23:41 GMT

Business Wire - PerkinElmer, Inc., a global leader in Health Sciences and Photonics, today announced the creation of the ViaCord Research Institute™ (VRI™) aimed at investigating new potential future uses of umbilical cord blood-derived stem cells.

Vasogen Provides Corporate Update

Thu, 03 Jul 2008 13:01:35 GMT

CNW Group - Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today announced that it has implemented additional restructuring plans to further reduce its cash burn rate.

Rosetta Genomics to Present at Collins Stewart Fourth Annual Growth Conference

Thu, 03 Jul 2008 12:30:30 GMT

PRNewswire - Rosetta Genomics Ltd (Nasdaq: ROSG), a leading developer of microRNA-based diagnostics and therapeutics, announced today it will present Collins Stewart Fourth Annual Growth Conference on Wednesday, July 9, at 8:30 am EST at the Mandarin Oriental Hotel in New York.

Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poor's Market Access Program

Thu, 03 Jul 2008 12:30:14 GMT

PRNewswire - Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), a leading developer and producer of plant extracts and pharmaceutical raw materials for use in pharmaceutical, nutraceutical and food production in China, announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight.

Senesco Signs a Supply Agreement for Polyplus-transfection's Delivery System

Thu, 03 Jul 2008 12:15:15 GMT

PRNewswire - Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today that it has contracted with Polyplus-transfection (Illkirch, France) to supply Polyplus's "in vivo-jetPEI" for systemic delivery of Senesco's combination therapy of siRNA against Factor 5A and a plasmid of the Factor 5A gene.

OSI Pharmaceuticals Announces Conversion Period for Convertible Notes

Thu, 03 Jul 2008 12:04:18 GMT

Business Wire - OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) announced today that its 2% Convertible Senior Notes due 2025 (the “notes”) are now convertible at the option of the holders and will remain convertible through September 30, 2008, the last trading day of the current fiscal quarter, as provided for in the Indenture governing the notes.

OncoGenex increases economic interest in lead cancer drug OGX-011

Thu, 03 Jul 2008 12:03:28 GMT

CNW Group - OncoGenex Technologies Inc. and Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that the companies have amended their agreement and OncoGenex has elected to independently develop its lead cancer drug OGX-011.

Allos Therapeutics to Present at the Collins Stewart Fourth Annual Growth Conference

Thu, 03 Jul 2008 12:01:51 GMT

Business Wire - Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that members of the Company’s senior management will present a corporate overview at the Collins Stewart Fourth Annual Growth Conference in New York.

APP Pharmaceuticals Receives Final Approvals for Additional Dosages of Granisetron Hydrochloride Injection, USP

Thu, 03 Jul 2008 12:01:29 GMT

Business Wire - APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading manufacturer of multi-source and branded injectable pharmaceutical products, today announced that it has received final approvals from the U.S.

Senesco Chooses VGXI to Produce Factor 5A Plasmid

Thu, 03 Jul 2008 12:00:25 GMT

PRNewswire - Senesco Technologies, Inc. ("Senesco" or the "Company") (Amex: SNT) announced today that it has contracted with VGXI, Inc. (The Woodlands, TX) ("VGXI") to supply the plasmid portion of the Company's combination therapy consisting of the Factor 5A gene and siRNA against Factor 5A.

Adolor Provides Update on Entereg(R) (alvimopan) OBD Program

Thu, 03 Jul 2008 11:30:20 GMT

Business Wire - Adolor Corporation (Nasdaq: ADLR) today issued an update on the Entereg® (alvimopan) Program for chronic opioid bowel dysfunction (OBD), under development in collaboration with GlaxoSmithKline (NYSE: GSK).

Principles, Techniques and Applications of Plant Biotechnology and Genetics

Thu, 03 Jul 2008 10:02:26 GMT

Business Wire - Research and Markets (http://www.researchandmarkets.com/resea rch/e750bb/plant_biotechnolog) has announced the addition of the "Plant Biotechnology and Genetics: Principles, Techniques and Applications" report to their offering.

AMDL Announces Investor Relations Presentation Available on Website

Thu, 03 Jul 2008 09:00:07 GMT

PRNewswire - AMDL, Inc. (Amex: ADL), a world leader in specialty pharmaceuticals headquartered in Tustin, Ca., with operations in Shenzhen, Jiangxi, and Jilin, China, announced today it has released its investor presentation which is available for viewing on the Company's website at http://www.am dl.com.

Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent

Thu, 03 Jul 2008 07:35:22 GMT

PRNewswire -

Nabriva Therapeutics Announces Appointment of New CEO

Thu, 03 Jul 2008 06:00:36 GMT

PRNewswire - Nabriva Therapeutics, a specialist in antibiotics development, announces that Dr. George Golumbeski has...

Anadis' Cancer Related Mucositis Project Awarded with VISTECH Grant

Wed, 02 Jul 2008 22:34:26 GMT

Business Wire - Anadis Ltd. (ASX:ANX; OTC:ANDIY) an Australian biopharmaceutical company has been awarded a product development grant for its Cancer-related Alimentary Mucositis project.

Microfluidics International Corporation Obtains New $2.5 Million Line of Credit in Support of Global Growth Strategy

Wed, 02 Jul 2008 22:01:18 GMT

Business Wire - Microfluidics International Corporation (OTCBB: MFIC) today announced that the Company has received a $2.5 million multi-year revolving line of credit from Silicon Valley Bank.

BIO Supports Commitment to Making July 4 Energy Independence Day

Wed, 02 Jul 2008 21:40:10 GMT

Business Wire - Through increased development and use of advanced biofuels combined with simple conservation strategies, the United States can extend its supply of homegrown energy and increase its energy security in 2009.

SpectraCell Laboratories Now Measures Vitamin C

Wed, 02 Jul 2008 21:32:02 GMT

PRNewswire - Effective immediately, SpectraCell Laboratories now measures functional levels of Vitamin C (ascorbate) using its proprietary FIA(TM) (Functional Intracellular Analysis) technology.

Boston Scientific Announces FDA Approval for PROMUS(TM) Everolimus-Eluting Coronary Stent System

Wed, 02 Jul 2008 21:23:01 GMT

PRNewswire - Boston Scientific Corporation (NYSE: BSX) today announced that the U.S. Food and Drug Administration (FDA) has approved the PROMUS(TM) Everolimus-Eluting Coronary Stent System for the treatment of coronary artery disease.

Paladin Labs and Procter & Gamble Pharmaceuticals Enter Into Canadian Co-Promotion Agreement for Seasonale(TM): First and Only Extended-Cycle Oral

Wed, 02 Jul 2008 21:00:30 GMT

Marketwire - Paladin Labs Inc. (TSX:PLB) and Procter & Gamble (P&G) Pharmaceuticals Canada, Inc., today announced that the companies have entered into a Canadian Co-Promotion Agreement for SEASONALE(TM) - the first and only extended-cycle oral contraceptive available in Canada.

PPD Announces Second Quarter 2008 Earnings Release, Webcast and Conference Call

Wed, 02 Jul 2008 20:37:22 GMT

Business Wire - PPD, Inc. (Nasdaq: PPDI) will release its second quarter 2008 financial results on Tuesday, July 22, 2008, after the market closes.

FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent

Wed, 02 Jul 2008 20:19:45 GMT

PRNewswire - Abbott today announced that the U.S. Food and Drug Administration (FDA) approved the XIENCE(TM) V Everolimus...

Biopure Announces Private Equity Financing

Wed, 02 Jul 2008 20:18:17 GMT

PRNewswire - Biopure Corporation (Nasdaq: BPUR) announced today that it has signed an agreement with purchasers for a private placement of its common stock and warrants for up to $2.3 million in tranches, assuming no exercise of the warrants.

ARYx Therapeutics, Inc. Announces Successful Results of QT Study on ATI-7505

Wed, 02 Jul 2008 20:16:25 GMT

Business Wire - ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced the results of an important cardiac safety study on its prokinetic agent, ATI-7505.

ARYx Therapeutics, Inc. Announces Procter & Gamble Exercises Option to End Collaboration on ATI-7505

Wed, 02 Jul 2008 20:16:04 GMT

Business Wire - ARYx Therapeutics, Inc., (NASDAQ:ARYX), a biopharmaceutical company, today announced that Procter & Gamble Pharmaceuticals, Inc. (P&G) has utilized a one-time thirty day cancellation option linked to the completion of a Thorough QT (TQT) study to end the collaboration agreement between the companies covering the late-stage development and commercialization of ATI-7505, a prokinetic agent in Phase 2 clinical trials for chronic constipation and functional dyspepsia.

GTC Biotherapeutics Receives Notice Related to Nasdaq Minimum Market Value Rule

Wed, 02 Jul 2008 20:15:23 GMT

Business Wire - GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) has received a Staff Deficiency Letter from The Nasdaq Stock Market notifying GTC that for the last 10 consecutive trading days the aggregate market value of GTCB common stock has fallen below $50 million, the minimum level required for continued listing on the Nasdaq Global Market, as specified by the Marketplace Rule 4450(b)(1)(A).

China Pharma Holdings, Inc. to Present at Collins Stewart Fourth Annual Growth Conference in New York on July 8, 2008 at 2:00 p.m. EDT

Wed, 02 Jul 2008 17:23:43 GMT

PRNewswire - China Pharma Holdings, Inc. (''China Pharma'') (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and branded bio- pharmaceutical products in China, today announced that the management will present at the Collins Stewart Fourth Annual Growth Conference on Tuesday, July 8th at 2:00 p.m. EDT.

Omrix Biopharmaceuticals Initiates Phase II Clinical Trial in Israel for Fibrin Pad Product Candidate

Wed, 02 Jul 2008 17:02:19 GMT

Business Wire - Omrix Biopharmaceuticals, Inc. (“Omrix” or the “Company”) (NASDAQ: OMRI) announced today that it has enrolled its first patient in a Phase II clinical trial in Israel for its Fibrin Pad product candidate.

Transcept Pharmaceuticals Appoints Key Senior Executives

Wed, 02 Jul 2008 15:46:55 GMT

PRNewswire - Transcept Pharmaceuticals, Inc. today announced the appointment of Terrence Moore to the position of Vice President, Marketing and Sales and Susan Koppy to the position of Vice President, Corporate Development. Both Mr. Moore and Ms. Koppy will report to President & Chief Executive Officer Glenn A. Oclassen. "We are pleased to welcome both Terry and Susan to the senior management team at Transcept," said Mr. Oclassen. "Terry's extensive neuroscience marketing and sales management experience will be a tremendous asset to Transcept as we prepare to commercialize our lead product candidate, Intermezzo(R).

Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedix's Med-eXpert(TM) System

Wed, 02 Jul 2008 15:39:11 GMT

PRNewswire - InforMedix Holdings, Inc. (OTC Bulletin Board: IFMX) is pleased to announce that Auburn University's Harrison School of Pharmacy has successfully incorporated InforMedix's Med-eMonitor and Med-eXpert Systems into its teaching curriculum, to teach the role of the community pharmacist in ensuring proper medication adherence and holistic health management and consulting.

Bioniche Pharma Acquires Baxter's ENLON(R) and ENLON-PLUS(R)

Wed, 02 Jul 2008 15:36:25 GMT

PRNewswire - Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Baxter Healthcare Corporation's ENLON product line, including:

Glaucoma Surgery Studied in Medicare Patients; New Hope for People With End-Stage Glaucoma

Wed, 02 Jul 2008 15:31:24 GMT

Business Wire - Ophthalmologists (Eye M.D.s) continue to develop treatments to help the more than three million Americans with glaucoma.

Pulmo BioTech Inc. Announces Possibility of MRI Application for PulmoBind

Wed, 02 Jul 2008 15:26:25 GMT

CNW Group - Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB) has announced the possibility of a new application for its PulmoBind Molecular Imaging technology.

On the Occasion of Its General Meeting, France Biotech Confirms Its Unifying Mission for All Innovative Small and Medium-Sized Life-Science Businesses

Wed, 02 Jul 2008 15:19:49 GMT

Business Wire - Following its Annual General Meeting, held on Tuesday 24th June, in Paris, France Biotech, the French life sciences industry association (www.france-biotech.org), reappointed its Board of Directors according to the statutes of association.

BIO to Co-Sponsor Import Safety Summit

Wed, 02 Jul 2008 15:18:57 GMT

Business Wire - The Biotechnology Industry Organization (BIO) will join with 12 other trade associations to sponsor an inter-industry summit on import safety on Wednesday, July 9, 2008 in Washington, D.C.

Providing Artificial Limbs to Amputees Leads TAPC to Be Named the "Best Place to Work" in Houston by Houston Business Journal

Wed, 02 Jul 2008 14:21:22 GMT

Business Wire - The Houston Business Journal recently announced that the Amputee and Prosthetic Center is the “Best Place to Work” among Houston-based companies with 1 to 100 employees.

Lev Pharmaceuticals to Present at the Collins Stewart 4th Annual Growth Conference

Wed, 02 Jul 2008 13:37:42 GMT

Business Wire - Lev Pharmaceuticals, Inc. ("Lev" or the "Company") (OTCBB:LEVP) announced today that Joshua Schein, Ph.D., chief executive officer of Lev will present at the Collins Stewart 4th Annual Growth Conference, being held July 8-10 at the Mandarin Oriental Hotel in New York City, NY.